Malignant neoplasm of peripheral nerves of left upper limb, including shoulder
ICD-10 C47.12 is a billable code used to indicate a diagnosis of malignant neoplasm of peripheral nerves of left upper limb, including shoulder.
C47.12 refers to malignant neoplasms that arise from the peripheral nerves in the left upper limb, including the shoulder region. These tumors can be classified as soft tissue sarcomas, which are malignant tumors originating from mesenchymal tissues. The peripheral nerves are critical for motor and sensory functions, and malignancies in this area can lead to significant morbidity. Symptoms may include pain, weakness, sensory loss, and functional impairment of the affected limb. Diagnosis typically involves imaging studies such as MRI or CT scans, followed by biopsy for histological confirmation. Treatment often requires a multidisciplinary approach, including surgical resection, radiation therapy, and chemotherapy, depending on the tumor's grade and stage. Grading of these tumors is essential, as it influences prognosis and treatment decisions. High-grade tumors are more aggressive and may require more intensive treatment strategies. The management of peripheral nerve tumors necessitates collaboration among oncologists, surgeons, radiologists, and rehabilitation specialists to optimize patient outcomes.
Detailed pathology reports, imaging studies, and treatment plans.
Diagnosis and management of soft tissue sarcomas, including staging and grading.
Ensure accurate documentation of tumor characteristics and treatment response.
Operative reports detailing surgical interventions and margins.
Surgical resection of malignant peripheral nerve tumors.
Document the extent of resection and any complications.
Used when excising a malignant peripheral nerve tumor.
Operative report detailing the tumor's location and margins.
Ensure the surgical approach is documented.
Tumor grading is crucial as it determines the aggressiveness of the cancer and influences treatment decisions. High-grade tumors may require more aggressive treatment compared to low-grade tumors.
